A genetic polymorphism in prostaglandin synthase 2 (8473, T-->C) and the risk of lung cancer.
Prostaglandin synthase 2 (PTGS2) mediated production of prostaglandins is an important step in the inflammatory response. In a population-based case-cohort study, we investigated the relationship between lung cancer and a polymorphism in PTGS2 at site 8473. Among 54,220 cohort members, 265 lung cancer cases and a comparison group of 272 individuals were identified. We found no overall significant association between the PTGS2 polymorphism and lung cancer risk, though the results indicated a lower risk in subjects carrying one copy (RR 0.87; 95% CI 0.61-1.25) or two copies (RR 0.58; 95% CI 0.30-1.12) of the variant allele compared with subjects carrying two copies of the wildtype allele. This tendency seemed to be strongest among the youngest subjects (50-55 years) with a RR on 0.48 (0.19-1.22) in carriers of one variant allele and 0.21 (0.04-1.07) in carriers of two variant alleles, and a significant trend (P=0.04). These results indicate that PTGS2 could be implicated in the development of lung cancer.
Sørensen
Mette
M
Institute of Cancer Epidemiology, The Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark. mettes@cancer.dk
Autrup
Herman
H
Tjønneland
Anne
A
Overvad
Kim
K
Raaschou-Nielsen
Ole
O
D000368:Aged; D016022:Case-Control Studies; D015331:Cohort Studies; D051546:Cyclooxygenase 2 / Q000235:genetics*; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008175:Lung Neoplasms / Q000209:etiology* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012307:Risk Factors
D051546:Cyclooxygenase 2